These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 32043796)

  • 1. Withholding the Introduction of Anti-Epidermal Growth Factor Receptor: Impact on Outcomes in RAS Wild-Type Metastatic Colorectal Tumors: A Multicenter AGEO Study (the WAIT or ACT Study).
    Palmieri LJ; Mineur L; Tougeron D; Rousseau B; Granger V; Gornet JM; Smith D; Lievre A; Galais MP; Doat S; Pernot S; Bignon-Bretagne AL; Metges JP; Baba-Hamed N; Michel P; Obled S; Vitellius C; Bouche O; Saban-Roche L; Buecher B; des Guetz G; Locher C; Trouilloud I; Goujon G; Dior M; Manfredi S; Soularue E; Phelip JM; Henriques J; Vernery D; Coriat R
    Oncologist; 2020 Feb; 25(2):e266-e275. PubMed ID: 32043796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial.
    Watanabe J; Muro K; Shitara K; Yamazaki K; Shiozawa M; Ohori H; Takashima A; Yokota M; Makiyama A; Akazawa N; Ojima H; Yuasa Y; Miwa K; Yasui H; Oki E; Sato T; Naitoh T; Komatsu Y; Kato T; Hihara M; Soeda J; Misumi T; Yamamoto K; Akagi K; Ochiai A; Uetake H; Tsuchihara K; Yoshino T
    JAMA; 2023 Apr; 329(15):1271-1282. PubMed ID: 37071094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis.
    Pietrantonio F; Fucà G; Rossini D; Schmoll HJ; Bendell JC; Morano F; Antoniotti C; Corallo S; Borelli B; Raimondi A; Marmorino F; Niger M; Boccaccino A; Masi G; Lonardi S; Boni L; de Braud F; Di Bartolomeo M; Falcone A; Cremolini C
    Oncologist; 2021 Apr; 26(4):302-309. PubMed ID: 33336844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A study-level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer.
    Heinemann V; Rivera F; O'Neil BH; Stintzing S; Koukakis R; Terwey JH; Douillard JY
    Eur J Cancer; 2016 Nov; 67():11-20. PubMed ID: 27592068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FOLFOX plus anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) is an effective first-line treatment for patients with RAS-wild left-sided metastatic colorectal cancer: A meta-analysis.
    Chen D; Li L; Zhang X; Gao G; Shen L; Hu J; Yang M; Liu B; Qian X
    Medicine (Baltimore); 2018 Mar; 97(10):e0097. PubMed ID: 29517682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of Anti-Epidermal Growth Factor Receptor Therapy Compared with Anti-Vascular Endothelial Growth Factor Therapy for Metastatic Colorectal Cancer: an Update Meta-Analysis of Randomized Clinical Trials.
    Wang JX; Wu HL; Zhu M; Zhou R
    Pathol Oncol Res; 2020 Jan; 26(1):159-166. PubMed ID: 29383654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer.
    Hecht JR; Cohn A; Dakhil S; Saleh M; Piperdi B; Cline-Burkhardt M; Tian Y; Go WY
    Clin Colorectal Cancer; 2015 Jun; 14(2):72-80. PubMed ID: 25982297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy, safety and genomic analysis of SCT200, an anti-EGFR monoclonal antibody, in patients with fluorouracil, irinotecan and oxaliplatin refractory RAS and BRAF wild-type metastatic colorectal cancer: a phase Ⅱ study.
    Yang L; Zhang W; Fan N; Cao P; Cheng Y; Zhu L; Luo S; Zong H; Bai Y; Zhou J; Deng Y; Ba Y; Liu T; Aili M; Yin X; Gu K; Dai G; Ying J; Shi J; Gao Y; Li W; Yu G; Xie L; Gai W; Wang Y; Meng P; Shi Y
    EBioMedicine; 2024 Feb; 100():104966. PubMed ID: 38217945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicians' Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, "Real-Life", Case-Control Study.
    Parisi A; Porzio G; Cannita K; Venditti O; Avallone A; Filippi R; Salvatore L; Tortora G; Ribelli M; Nigro O; Gelsomino F; Spallanzani A; Zurlo V; Leo S; Dell'Aquila E; Claudia F; Lombardi P; Keränen SR; Aimar G; Depetris I; Giampieri R; Morelli C; De Tursi M; Tinari N; Di Pietro FR; De Galitiis F; Zanaletti N; Troiani T; Vitale P; Garajova I; Ghidini M; Spinelli GP; Zoratto F; Roberto M; Ierino D; Petrillo A; D'Orazio C; Ficorella C; Cortellini A
    Clin Colorectal Cancer; 2021 Dec; 20(4):318-325. PubMed ID: 34380594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary tumour side as a driver for treatment choice in RAS wild-type metastatic colorectal cancer patients: a systematic review and pooled analysis of randomised trials.
    Rossini D; Boccaccino A; Carullo M; Antoniotti C; Dima G; Ciracì P; Marmorino F; Moretto R; Masi G; Cremolini C
    Eur J Cancer; 2023 May; 184():106-116. PubMed ID: 36913832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
    Tol J; Punt CJ
    Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Delaying the Addition of Anti-EGFR in First Line of RAS Wild-Type Metastatic Colorectal Cancer: A Propensity-Weighted Pooled Data Analysis.
    Palmieri LJ; Buchler T; Meyer A; Veskrnova V; Fiala O; Brabec P; Baranova J; Coriat R
    Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment outcome comparisons of first-line targeted therapy in patients with KRAS wild-type metastatic colorectal cancer: A nationwide database study.
    Liang YH; Chen KH; Shao YY
    Cancer Med; 2023 Jul; 12(14):15176-15186. PubMed ID: 37325970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials.
    Arnold D; Lueza B; Douillard JY; Peeters M; Lenz HJ; Venook A; Heinemann V; Van Cutsem E; Pignon JP; Tabernero J; Cervantes A; Ciardiello F
    Ann Oncol; 2017 Aug; 28(8):1713-1729. PubMed ID: 28407110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis.
    Pietrantonio F; Cremolini C; Petrelli F; Di Bartolomeo M; Loupakis F; Maggi C; Antoniotti C; de Braud F; Falcone A; Iacovelli R
    Crit Rev Oncol Hematol; 2015 Oct; 96(1):156-66. PubMed ID: 26088456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of first-line anti-epidermal growth factor receptor therapy compared with anti-vascular endothelial growth factor therapy in advanced colorectal cancer: a meta-analysis of randomized clinical trials.
    Khattak MA; Martin H; Davidson A; Phillips M
    Clin Colorectal Cancer; 2015 Jun; 14(2):81-90. PubMed ID: 25666296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer.
    Schwartzberg LS; Rivera F; Karthaus M; Fasola G; Canon JL; Hecht JR; Yu H; Oliner KS; Go WY
    J Clin Oncol; 2014 Jul; 32(21):2240-7. PubMed ID: 24687833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer.
    Hurwitz HI; Yi J; Ince W; Novotny WF; Rosen O
    Oncologist; 2009 Jan; 14(1):22-8. PubMed ID: 19144677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ramucirumab plus FOLFIRI as second-line treatment for patients with RAS wild-type metastatic colorectal cancer previously treated with anti-EGFR antibody: JACCRO CC-16.
    Yasui H; Okita Y; Nakamura M; Sagawa T; Watanabe T; Kataoka K; Manaka D; Shiraishi K; Akazawa N; Okuno T; Shimura T; Shiozawa M; Sunakawa Y; Ota H; Kotaka M; Okuyama H; Takeuchi M; Ichikawa W; Fujii M; Tsuji A
    ESMO Open; 2023 Oct; 8(5):101636. PubMed ID: 37703596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A meta-analysis of efficacy and safety data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in adult patients with RAS wild-type metastatic colorectal cancer by sidedness.
    Yoshino T; Hooda N; Younan D; Muro K; Shitara K; Heinemann V; O'neil BH; Herrero FR; Peeters M; Soeda J; Suh M; Reichert H; Mezzi K; Fryzek J; Chia V; Rehn M; Stintzing S
    Eur J Cancer; 2024 May; 202():113975. PubMed ID: 38442645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.